News Drug Development

MediGene, Inc. Drug Extends Pancreatic Cancer Survival

September 16, 2008 |

1 min read

LONDON, Sept 16 (Reuters) - Patients with inoperable pancreatic cancer live substantially longer when given MediGene's experimental drug EndoTAG-1 on top of standard chemotherapy, according to clinical trial results.

Clinical research Phase 2 Europe

MORE ON THIS TOPIC

Illustration of scales of justice tipping to one side

Lung cancer

Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit

September 15, 2026

·

3 min read

·

Tristan Manalac

United Kingdom and China flag together realtions textile cloth fabric texture

Deals

GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M

September 15, 2026

·

2 min read

·

Gabrielle Masson

Model of the lungs with the diseased part. Cancer or Ground glass opacity GGO.

Lung cancer

Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs

September 14, 2026

·

4 min read

·

Gabrielle Masson

This 3D rendering encapsulates the concept of a winning strategy in business, emphasizing productivity, innovation, and the importance of female leadership. The imagery represents the synergy of teamwork, where diverse ideas and collaborative efforts drive success and growth. It highlights the critical role of women in leadership positions, showcasing their contributions to strategic planning and innovation. This visual serves as an inspiring representation of how inclusive leadership and innovative thinking can propel a business toward achieving its goals and maintaining a competitive edge in the market.

Psychedelics

Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’

September 14, 2026

·

3 min read

·

Heather McKenzie